Two Day Biomarker and Companion Diagnostics Conference (San Diego, United States – February 7-8, 2019)

Dublin, Dec. 19, 2018 (GLOBE NEWSWIRE) -- The "Biomarker and Companion Diagnostics Conference" conference has been added to's offering.

Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. Major developments have been seen in immune therapies where breakthroughs will be appearing soon.

The 4th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th-8th February 2019 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

Key Highlights

  • Clinical biomarker identification and qualification
  • Biomarkers and personalized medicine
  • Assay development and validation
  • NGS and novel technologies in biomarker discovery
  • Commercialization of biomarkers in therapeutic and CDx applications

Why Attend

  • 30+ experts from academia and industry presenting their current work in Biomarkers
  • Latest updates on regulatory guidelines and approvals
  • Case studies from experts who have successfully created and developed a biomarker
  • Facilitated networking sessions to ensure quality interactions
  • One on one query handling by biomarker experts
  • Opportunity to develop long-lasting business relationships and networking opportunities with senior peers

Who Should Attend:

Researchers, scientists, clinicians, academicians and professionals from

  • Pharmaceutical companies
  • Bio-pharma companies
  • Universities and Research institutes

Working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics


Day 1

08:15 Registration

08:55 Welcome note

09:00 Opening Remarks from the Chairman

09:10 Keynote Presentation: Business of Fit For Purpose: From sample management to validation to final sample analysis data
Iman Jilani, Director, Oncology Clinical Assay Group, Early Development Translational and Immuno-Oncology, Global Product Development, Pfizer

09:40 Biomarker Candidates to Qualified Markers - Approaches and Case Studies

  • Biomarker identification and prioritization approaches
  • Qualifying biomarkers -challenges and rewards
  • Therapeutic case studies

Katherine Call, Head, Proteogenomics, Sanofi Genzyme

10:10 Streamlined CDx - A Proven Strategy to Accelerate Drug Approvals

  • Companion Diagnostics (CDx) represents critical milestone in precision diagnostics and plays pivotal role in the validation of targeted therapies
  • Traditional CDx development models involve multiple partners adding complexity and increasing risk which could affect drug approvals
  • Streamlined CDx model has been shown to accelerate FDA, EMA and PMDA approvals of new targeted therapies

Jeff Miller, CEO, CSO, Invivoscribe

10:25 Morning Refreshments and Poster Presentation - One-to-One Networking Meetings

11:10 Functional proteome array screening strategies for biomarker discovery

  • Self-assembling protein microarrays can be used to study protein-protein interactions.
  • Recent work has focused on using the arrays to explore post translational modification of proteins
  • Experiments have focused on using protein microarrays to search for antibody responses in patients with cancer, autoimmune and infectious diseases

Joshua LaBaer, Director, Executive Director and Professor, University of Arizona

11:40 Development of PD Biomarkers to Support Therapeutics for rare diseases

  • Incorporation of PD biomarkers into clinical trials to demonstrate compound binding to its molecular target and the subsequent modulation of downstream pathways enables early testing of compound mechanism and provides a data-driven framework for decisions on compound progression.
  • Identification and validation of such fit-for-purpose' PD biomarkers, and their use and value in dose selection and accelerating the clinical development

Mark Ma, Head, Bioanalytical and Biomarker Development, Alexion Pharmaceuticals

12:10 Leveraging immunoaffinity-proteomics to identify and validate next-generation drug-induced kidney injury biomarkers

  • Histopathology remains the gold standard' by which drug-induced kidney injury is established as a preclinical study finding
  • Conventional and newer biomarkers must be used together to establish translational risks as evidence to terminate a drug candidate prior to first-in-human studies
  • Triple X Proteomics antibodies consists of epitopes that span animal models and humans, offering a single platform to evaluate drug-induced biomarker responses across different species

James McDuffie, Scientific Director, Janssen Research & Development

12:40 Non-invasive diagnosis of lung cancer

  • Genomic screens to identify circulating biomarkers for lung cancer detection.
  • Cancer testis antigens that distinguish malignant from benign lung nodules.
  • Application of artificial intelligence in lung cancer detection.

Qihong Huang, Senior Principal Scientist, Boehringer Ingelheim

13:10 Lunch and Poster Presentation - One-to-One Networking Meetings

14:10 Presentation by Ken Bloom, Chief Medical Officer, Ambry Genetics

14:40 Minimizing PreAnalytical Variables to Improve Diagnostic Sample Quality
Thomas Briggs, Senior Key Account and Business Development Manager, Becton Dickinson

14:55 High-Specificity and High-Throughput liquid biopsy Technology for Non-Invasive Cancer and Prenatal Diagnostics

  • Data to demonstrate the technical performance of BioFludica's THE LIQUID SCAN Technology
  • Instrumentation and high-throughput scalability of the system and supply chain to address large patient cohort analysis
  • Address the implementation of the THE LIQUID SCAN for solid cancer, leukemia and prenatal diagnostics

Rolf Muller, CEO, BioFluidica

15:10 Solution Provider Presentation

15:25 What do we know about turning immunologically cold to hot tumors?

  • Predicting responses to immunotherapy with PD-1
  • Strategies for treating PD-1 refractory patients
  • Immune profiling of tumors

Adil Daud, Professor of Medicine and Dermatology, University of California San Francisco

15:40 Afternoon Refreshments and Poster Presentation - One-to-One Networking Meetings

16:25 Peripheral metabolome and cognitive function

  • Plasma metabolome can detect preclinical Alzheimer's disease very accurately
  • Plasma metabolome detects over adults with supernormal cognitive scores
  • Plasma metabolome reflects injury and functions of the CNS

Howard Federoff, Professor of Neurology, University of California

16:55 Panel Discussion: Use of biomarkers in clinics-success and challenges of getting a good biomarker
How do we identify patients for the biomarker combination trials?

17:25 Closing Remarks from the Chairman

17:30 Drinks Reception & Networking

Day 2

08:15 Registration

08:55 Welcome note

09:00 Opening Remarks from the Chairman

09:10 Keynote Presentation: Regulatory strategy/guidelines in drug-diagnostic co-development

09:40 From Clinical Trial Assay to Companion Diagnostics: An assay to determine HTT single nucleotide polymorphisms (SNPs) linked to the expanded CAG repeats in Huntington's disease

  • Huntington disease (HD) is a hereditary genetic disease caused by an expanded cytosine-adenine-guanine (CAG) triplet repeat in the huntingtin (HTT) gene that results in production of mutant HTT (mHTT) protein, which is believed to contribute to HD pathology
  • The unique association of certain SNPs with the expanded CAG allele opens the possibility of targeting these SNPs with specific personalized treatments intended to selectively lower mHTT protein (while preserving wild-type HTT) and potentially treat HD
  • Wave Life Sciences is developing investigational stereopure antisense oligonucleotides that are designed to selectively target SNP1 and SNP2, respectively, on the mHTT allele to selectively lower the mHTT gene transcript
  • A long-range sequencing and SNP phasing assay to support clinical studies and the approach for the development of companion diagnostic will be presented
  • Jaya Goyal, Vice President, Bioanalytical, Pharmacology and Biomarker Development, Wave Lifesciences

10:10 Genomic architecture differences at the HTT locus underlie symptomatic and pre-symptomatic cases of Huntington's disease

  • There is a high clinical need for a molecular tool to assess disease progression in HD
  • Epigenetic changes identified by EpiSwitch can differentiate between healthy individuals, pre-symptomatic HD patients, and symptomatic HD patients
  • Following a study published earlier this year in amyotrophic lateral sclerosis (ALS), this is the second successful application of EpiSwitch in a neurodegenerative condition

Will Westra, Senior Director of Business Development (USA), Oxford BioDynamics

10:25 Solution Provider Presentation

10:55 Morning Refreshments and Poster Presentation - One-to-One Networking Meetings

11:30 Next-generation CAR T-cells

  • TALEN Gene Editing for Allogeneic CAR T-Cell Products
  • Initial clinical proof of concept for Off-the-Shelf CAR T-cells
  • Central role for biomarkers in the development of of novel T-cell therapeutic agents

Julianne Smith, Head, Translational Medicine, Cellectis

12:00 Solution Provider Presentation

12:30 Primary and secondary mechanisms of resistance to ant-CD19 CAR T cell therapy in NHL

  • Product related
  • Tumor related
  • Treatment related

John Rossi, Director, Translational Sciences, Kite Pharma

13:00 Endogenous Anti-Inflammatory Very-Long-Chain Dicarboxylic Acids: Potential Chemopreventive Lipids

  • Very-long-chain dicarboxylic acids (VLCDCA) are characterized for the first time in human biofluids
  • VLCDCA 28:4 was shown to be an anti-inflammatory lipid
  • VLCDCA 28:4 is decreased in the plasma of patients with colorectal, kidney, and pancreatic cancers
  • VLCDCA 28:4 is a potential biomarker of these deep organ cancers
  • VLCDCA 28:4 prodrugs represent a new potential anti-inflammatory drug class

Paul Wood, Director, Metabolomics Unit, Professor, Associate Dean of Research, Lincoln Memorial University

13:30 Lunch and Poster Presentation - One-to-One Networking Meetings

14:30 Solution Provider Presentation

15:00 Integrating companion diagnostic assay technologies into drug development

15:30 Clinical change of paradigm in liquid biopsies

16:00 Closing Remarks from the Chairman

16:05 End of Conference

For more information about this conference visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Biomarkers